Chemoprevention of prostate cancer: Current status and future directions

Cancer and Metastasis Reviews

Volumn 21, Issue 3-4, 2002, Pages 297-309

  Lieberman, Ronald ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Division of Cancer Prevention   (United States)

Author keywords

Antiandrogens; Antiestrogens; Biomarkers; Chemoprevention; Clinical trials; Cohorts; COX 2 inhibitor; Designs; GSTPI agents; HGPIN; Prostate cancer; PSA; Receptor tyrosine kinase

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALITRETINOIN; ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; BEXAROTENE; CASPASE; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; HISTONE DEACETYLASE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; ISOFLAVONE DERIVATIVE; LONAFARNIB; LYCOPENE; MITOGEN ACTIVATED PROTEIN KINASE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; NATURAL PRODUCT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; STEROID RECEPTOR; SULINDAC SULFONE; UNINDEXED DRUG; VASCULOTROPIN;

CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; DNA MICROARRAY; FUTUROLOGY; GENE EXPRESSION; GENETIC RISK; HORMONE RESISTANCE; HUMAN; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; REVIEW; SECONDARY PREVENTION;

ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; FORECASTING; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0036946128     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021267128567     Document Type: Review

References (69)

1. Greenlee RT, Hill-Harmon MB, Murray T. Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001
2. Sakr WA, Haas GP, Cassin BJ, Pontes JE, Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379-385, 1993
3. Greenwald P, Lieberman R: Chemoprevention trials for prostate cancer. In: Chung L, Isaacs W, Simons J (eds) Prostate Cancer in the 21st Century, Humana Press Inc, Totowa, NJ, 2001, pp 499-518
4. Kelloff GJ, Lieberman R, Brawer MK, Crawford ED, Miller G: Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostate Dis 2: 27-33, 1999
5. Lieberman R, Bermejo C, Akaza H. Greenwald P, Fair W. Thompson I: Progress in prostate cancer chemoprevention: Modulators of promotion and progression. Urol 58: 835-842, 2001
6. Bostwick DG, Brawer MK: Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59: 788-794, 1987
7. Qian J, Jenkins RB, Bostwick DG: Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluoresence in sire hybridization. Eur Urol 35: 479-483, 1999
8. Bostwick DG: Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol 30: 145-152, 1996
9. De Marzo AM, Marchi VL, Epstein JL. Nelson WG: Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Path 155: 1985-1992, 1999
10. Nelson WG, De Marzo AM, DeWeese TL: The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urol 57(4A): 39-46, 2001
11. Bartels PH, Montironi R, Hamilton PW, Vaught DL, Bartelds HG: Nuclear chromatin texture in prostatic lesions. II. PIN and malignancy associated changes. Anal Quant Cytol Histol 20: 397-406, 1998
12. Powell IJ, Meyskens FL: African american men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials. Urol 57(4A): 178-181, 2001
13. Lieberman R: Prostate cancer chemoprevention: Strategies for designing efficient clinical trials. Urol 57(4A): 224-229, 2001
14. Crawford ED, Rosenbasum M, Ziada AM, Lange PH: Overview: Hormone refractory prostate cancer. Urol 54(6A): 1-7, 1999
15. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tiley WD, Aspwall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen M: Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443, 1995
16. Lieberman R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM: Executive summary of the national cancer institute workshop: Highlights and recommendations. Urol 57(4A): 4-28, 2001
17. Moria GR, Tindall DJ: Ligand dependent and independent activation of the androgen receptor. In: Chung L, Isaacs W, Simons J (eds) Prostate Cancer in the 21st Century, Humana Press Inc. Totowa, NJ, 2001, pp 219-239
18. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001
19. Steiner MS, Raghow S, Neubauer BL: Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urol 57(4A): 68-73, 2001
20. Folkman J: Tumor angiogenesis. Adv Cancer Res 43: 175-203, 1985
21. Walczak J, Wood H, Wilding G, Williams T, Bishop CW, Carducci M: Prostate cancer prevention strategies using antiproliferative or differentiating agents. Urol 57(4A): 81-86, 2001
22. Myers C, Koki A, Pamukcu R, Wechter W, Padley RJ: Proapoptotic anti-inflammatory drugs. Urol 57(4A): 73-77, 2001
23. Bergan RC, Waggle DH, Carter SK, Horak I, Slichenmyer W. Myers M: Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer. Urol 57(4A): 77-81, 2001
24. Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW: Other novel agents: Rationale and current status as chemopreventive agents. Urol 57(4A): 86-90, 2001
25. Trump DL, Waldstreicher JA, Kolvenbag G, Wissel PS, Neubauer BL: Androgen antagonists: Potential role in prostate cancer prevention. Urol 57(4A): 64-68, 2001
26. Pantuck AJ, Zisman A, Henderson D, Wilson D, Schreiber A, Belldegrun A: New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions. Urol 57(4A): 95-100
27. Nelson WG, Wilding G: Prevention agent development: Criteria and pipeline for candidate chemoprevention agents. Urol 57(4A): 56-64, 2001
28. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A: Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgeneic mice (TRAMP). Cancer Res 61: 6777-6782, 2001
29. Fetter F, Simons JW, Rodriguez R: Human gene therapy for urological oncology. In: Chung L, Isaacs W, Simons J (eds) Prostate Cancer in the 21st Century, Humana Press Inc, Totowa, NJ, 2001, pp 483-497
30. Alberts S, Blute M: Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia. Urol 57(4A): 188-190, 2001
31. Clark LC, Marshall JR: Randomized controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia. Urol 57(4A): 185-187, 2001
32. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Meal 341: 1781-1788, 1999
33. Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick D: Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urol 44: 91-95, 1994
34. van der Kwast Th H, Labrie F, Tetu B: Prostatic intraepithelial neoplasia and endocrine manipulation. Eur Urol 35: 508-510, 1999
35. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG: Design of the prostate cancer prevention trial (PCPT). Control Clin Trials 16: 150-163, 1995
36. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chin E, Ford L. Wolmark N: Tamoxifen for prevention of breast cancer. Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371-1388, 1998
37. Cote RJ, Skinner EC, Salem CE, Mertes SJ, Stanczyk FZ, Henderson BE, Pike MC, Ross RK: The effect of finasteride on the prostate gland in men with elevated serum prostate specific antigen (PSA) levels. Brit J Cancer 78: 413-418, 1998
38. Clark LC, Dalkin B, Krongrad A, Combs GF, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Roudder J: Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 81: 730-734, 1998
39. Heinonen OP, Albanes D, Virtamo J, Taylor, PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK: Prostate cancer and supplementation with alpha tocopherol and beta carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 90: 440-446, 1998
40. Williams ED, Brooks JD: New molecular approaches for identifying novel targets, mechanisms and biomarkers for prostate cancer chemoprevention agents. Urol 57(4A): 100-103, 2001
41. Bai G, Kaspar S, Matusik RJ, Rennie PS, Moshier JA, Krongrad A: Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells. J Androl 19: 127-135, 1998
42. Mohan RR, Challa A, Gupta S, et al.: Overexpression of ornithine decarboxylase in prostate cancer and prostatic fluid in humans. Clin Cancer Res 5: 143-147, 1999
43. Simoneau AR, Gerner EW, Phung M, McLaren CE, Meyskens FL: Alpha-difluoromethylornithine (DFMO) suppresses polyamine levels in the human prostate. Results of a one-month phase II A chemoprevention trial. J Natl Cancer Inst 93: 57-59, 2001
44. Dunzendorfer U, Releya N, Whitmore WF: Some effects of inhibitors of polyamines synthesis on experimental prostatic cancer. Arzneim Forsch Drug Res 34: 36-39, 1984
45. Coffey D: Similarities of prostate and breast cancer: Evolution, diet and estrogens. Urol 57(4A): 31-39, 2001
46. Denis L, Morton MS, Griffiths K: Diet and its preventive role in prostatic disease. Eur Urol 35: 377-387, 1999
47. Sharma OP, Adlercreutz H, Strandberg JD, Zirkin BR, Coffey DS: Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol 43: 557-563, 1992
48. Raghow S, Steakley M, Greenberg N, Steiner MS: Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Res 60: 4093-4097, 2000
49. Richie JP: Anti-androgens and other hormonal therapies for prostate cancer. Urol 54(6A): 15-18, 1999
50. Staiman VR, Lowe FC: Tamoxifen for flutamide and finasteride induced gynecomastia. Urol 50: 929-933, 1997
51. Yang M, Sytkowski AJ: Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res 58:3150-3153, 1998
52. Jiang C, Wang Z, Ganther H, Lu J: Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 61: 3062-3070, 2001
53. Yoshizawa K, Willett WC, Morris SJ: Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 90:1219-1224, 1998
54. Nelson JE, Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs). Results of a case control study. Oncol Rep 7:169-176, 2000
55. Ripple MO, Henry WF, Rago RP, Wilding G: Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89: 40-48, 1997
56. Kirschenbaum A, Liu XH, Yao S, Levine AC: The role of cyclooxygenase-2 in prostate cancer. Urol 58(2A): 127-131, 2001
57. Liu XH, Yao S, Kirschenbaum A, Levine AC: NS398, a selective cyclooxygenase-2 inhibitor induces apoptosis and down-regulates bcl-2 expression in LNCAP cells. Cancer Res 58: 4245-4249, 1998
58. Grouse LH, Munson PJ, Nelson PS: Sequence database and microarrays as tools for identifying prostate cancer biomarkers. Urol 57(4A): 154-160, 2001
59. Paweletz CP, Liotta LA, Petricoin EF III: New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urol 57(4A): 160-164, 2001
60. Kurhanewicz J, Swanson MG, Wood PJ, Vigneron DB: Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials. Urol 57(4A): 124-129, 2001
61. Rubin MA: Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate cancer. J Path 195: 80-86, 2001
62. Meehan KL, Holland JW, Dawkins HJS: Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50: 54-63, 2002
63. Ahram M, Best CJM, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF III, Emmert-Buck MR: Proteomic analysis of human prostate cancer. Mol Carcinog 33: 9-15, 2002
64. Lee JL, Lieberman R, Sloan JA, Piantadosi S, Lippman SM: Design considerations for efficient prostate cancer chemoprevention trials. Urol 57(4A): 205-213, 2001
65. Keegan P, Loughman BF: Early clinical trials of chemopreventive and biologic agents: Designs, populations and endpoints. Urol 57(4A): 216-220, 2001
66. Beitz J: Trial endpoints for drug approval in oncology: Chemoprevention. Urol 57(4A): 213-216, 2001
67. Lefkowitz GK, Sidhu GS, Torre P, Lepor H, Taneja SS: Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urol 58: 999-1003, 2001
68. Keetch DW. Catalona WJ, Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostatic specific antigen values. J Urol 151: 1571-1574, 1994
69. Byar D, Piantadosi S: Factorial designs for randomized clinical trials. Cancer Treat Rep 69: 1055-1063, 1985